Nurix Therapeutics
NRIX
118 hedge funds and large institutions have $561M invested in Nurix Therapeutics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 51 increasing their positions, 23 reducing their positions, and 8 closing their positions.
173,900% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $1K
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
122% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 23
11% more funds holding
Funds holding: 106 → 118 (+12)
1% less capital invested
Capital invested by funds: $568M → $561M (-$7.49M)
8.58% less ownership
Funds ownership: 100.1% → 91.52% (-8.6%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$8.04M |
| 2 |
Goldman Sachs
New York
|
+$7.81M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.24M |
| 4 |
BlackRock
New York
|
+$5.82M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$24.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.1M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$14.6M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$8.58M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.76M |
NRIX Hedge Fund Activity: Q3 2022 in Review
118 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2022, worth a combined $561M — down 1.3% from $568M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NRIX positions and 8 closed out — a net gain of 12 holders — while 51 added to existing stakes and 23 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $8.04M. The largest seller was TRV GP III, exiting entirely with an estimated $24.4M sold.
- 118 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2022, up from 106 in Q2 2022.
- Funds reported $561M of Nurix Therapeutics stock for Q3 2022, down 1.3% quarter-over-quarter.
- 20 funds opened new Nurix Therapeutics positions in Q3 2022 and 8 closed out, a net change of +12 holders.
- The largest Nurix Therapeutics buyer in Q3 2022 was ARK Investment Management, an estimated $8.04M added.
- The largest Nurix Therapeutics seller in Q3 2022 was TRV GP III, an estimated $24.4M sold.
Based on aggregated 13F filings for Q3 2022.